Yahoo
    Shenzhen - Delayed Quote CNY

    Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ)

    59.06 -2.81 (-4.54%)
    At close: 3:04:58 PM GMT+8
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for 300832.SZ
    • Previous Close 61.87
    • Open 59.67
    • Bid 59.09 x --
    • Ask 59.10 x --
    • Day's Range 59.00 - 61.50
    • 52 Week Range 37.50 - 67.18
    • Volume 7,953,948
    • Avg. Volume 6,812,639
    • Market Cap (intraday) 46.405B
    • Beta (5Y Monthly) -0.34
    • PE Ratio (TTM) 25.68
    • EPS (TTM) 2.30
    • Earnings Date --
    • Forward Dividend & Yield 1.20 (1.94%)
    • Ex-Dividend Date May 27, 2026
    • 1y Target Est 69.74

    Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay analyzers, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was founded in 1995 and is based in Shenzhen, China.

    www.snibe.com

    2,785

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Medical Devices

    Industry

    More about Shenzhen New Industries Biomedical Engineering Co., Ltd.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

    YTD Return

    300832.SZ
    7.70%
    SSE Composite Index (000001.SS)
    8.34%

    1-Year Return

    300832.SZ
    0.68%
    SSE Composite Index (000001.SS)
    8.01%

    3-Year Return

    300832.SZ
    6.70%
    SSE Composite Index (000001.SS)
    20.89%

    5-Year Return

    300832.SZ
    51.19%
    SSE Composite Index (000001.SS)
    3.78%

    Earnings Trends

    View More

    Earnings Per Share (GAAP)

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q3 FY26
    Revenue 1.28B
    Earnings 522.88M
    Profit Margin 40.84%

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    Q3

    FY26

    0
    500M
    1B
    34.0%
    36.0%
    38.0%
    40.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    62.00
    69.74 Average
    59.06 Current
    87.20 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      37.24%

    • Return on Assets (ttm)

      13.02%

    • Return on Equity (ttm)

      19.91%

    • Revenue (ttm)

      4.85B

    • Net Income Avi to Common (ttm)

      1.81B

    • Diluted EPS (ttm)

      2.30

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      2.74B

    • Total Debt/Equity (mrq)

      0.03%

    • Levered Free Cash Flow (ttm)

      551.59M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    300760.SZ Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    179.29 -1.35%
    300529.SZ Jafron Biomedical Co.,Ltd.
    18.91 +6.90%
    300122.SZ Chongqing Zhifei Biological Products Co., Ltd.
    13.87 +2.82%
    002821.SZ Asymchem Laboratories (Tianjin) Co., Ltd.
    137.48 +2.13%
    300759.SZ Pharmaron Beijing Co., Ltd.
    42.76 +3.36%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: